Arkolith/Insider Trading/STRO/Form 4

Leyman Barbara

Chief Business OfficerSUTRO BIOPHARMA, INC. (STRO) · full profile →Form 4 · filed Aug 26, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 8, 2025Option exercise(M)25K—$025K
Jul 8, 2025Tax withholding(F)9K$0.78$7K16K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 8, 2025Option exercise(M)25K—$075K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-023084) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML